The signal transduction pathway of multi-target kinase inhibitors as anticancer agents in clinical use or in phase III

Yaoxue Xuebao

Volumn 44, Issue 3, 2009, Pages 242-257

  Wu, Wen ^a   Lu, Cheng ^a   Chen, Si Yu ^a   Yu, Nie Fang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Anticancer agents; Kinase inhibitor; Multi target; Signal transduction; Tumor

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AXITINIB; DASATINIB; DEFOROLIMUS; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; MIDOSTAURIN; MOTESANIB; NILOTINIB; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; RUBOXISTAURIN; SORAFENIB; SUNITINIB; VANDETANIB; VATALANIB;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; PHASE 3 CLINICAL TRIAL; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 67249120693     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Levitzki A. Targeting signal transduction for disease therapy [J]. Med Oncol, 1997, 14: 83-89.
2. Wermuth CG. Multitargeted drugs: The end of the 'one- target-one-disease' philosophy? [JI. Drug Discov Today, 2004, 9: 826-827.
3. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) [J]. Cancer Res, 2002, 62: 4236-4243.
4. Capdeville R, Buchdunger E, Zimniermann J, et al. Glivec (ST1571, imatinib), a rationaly developed, targeted anticancer drug [J]. Nat Rev Drug Discov, 2002, 1: 493-502.
5. Bilanges B, Torbett N, Vanhaesebroeck B. Killing two kinase families with one Stone [J]. Nat Chem Biol, 2008, 4: 648-649.
6. Buchdunger E, Melt H, Meyer T, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative [J]. Cancer Res, 1996, 56: 100-104.
7. Kraman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity [J]. Nat Biotechnol, 2008, 26: 127-132.
8. Advani AS, Pendergast AM. BCR-Abl variants: Biological and clinical aspects [J]. Leuk Res, 2002, 26: 7 13-720.
9. Czechowska A, Poplawski T, Drzewoski J, et al. Imatinib (ST1571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes [J]. Chem Biol Interact, 2005, 152: 139-150.
10. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs [J]. Eur J Cancer, 2003, 39: 1348-1354.
11. Bellezza I, Bracarda 5, Caserta C, et al. Targeting of EGFR tyrosine kinase by ZD1839 ("Gefitinib") in androgen responsive prostate cancer in vitro [J]. Mol Genet Metab, 2006, 88: 114-122.
12. She QB, Solit D, Basso A, et al. Resistance to gefitinib in PTEN-Null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3-kinase/Akt pathway signaling [J]. Clin Cancer Res, 2003, 9: 4340-4346.
13. Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: Mechanisms of activation and signaling [J]. Exp Cell Res, 2003, 284: 3 1-53.
14. Luo QJ, Ma T, Yin QY. Gefitinib: A target-based anticancer drug for treatment of advanced lung cancer [J]. J Ningxia Med Coll (Japanese Source) 2007, 6: 642-643.
15. Bose R, Zhang XW. The ErbB kinase domain: Structural perspectives into kinase activation and inhibition [J]. Exp Cell Research, in press.
16. de Bono JS, Rowinsky EK. The ErbB receptor family: A therapeutic target for cancer [J]. Trends Mol Med, 2002, 8: 19-26.
17. Lu S, Li ZM, Cheng BJ, et al. The evaluations of advanced non-small cell lung cancer patients treated with erlotnib [J]. China Oncol (Japanese Source) 2007,9:711-715.
18. Wan PT, Garnett Mi, Roe SM, et al, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF [J]. Cell, 2004, 116: 855-867.
19. Huether A, Baradari V, Schuppan D, et al. Sorafenib alone or as combination therapy for growth control of cholangiocarci noma[J]. BiochemPharmacol, 2007, 73: 1308-1317.
20. Rahmani M, Davis EM, Bauer C, et al. Apoptosis induced by the kinase inhibitor BAY43-9006 in human leukemia cells invovies down-regulation of MCL- 1 through inhibition of translation [J]. J Biol Chem, 2005, 280: 35217-35227.
21. Wang F, Fu lw. Research advances in sorafenib: A multiple targeted anti-tumor agent [J]. Chin Pharmacol Bull (Japanese Source)2008, 24: 1117-1120.
22. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo [J]. Blood, 2003, 101: 3597-3605.
23. Faivre 5, Demetri G, Sargent W, et al. Molecular basis for sunitinib efficacy and future clinical development [J]. Nat Rev Drug Discov, 2007, 6: 734-745.
24. Wang CM, Shi YQ. The application of target-based anticancer drug -sunitinib in treatment of GIST [J]. Tumor (Japanese Source)2008, 28: 268-271.
25. Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN1O7) therapy failure [J]. Blood, 2007, 109: 497-499.
26. Tokarski JS, Newitt JA, Chang CY, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinibresistant ABL Mutants [J]. Cancer Res, 2006, 66: 5790-5797.
27. Blake S, Hughes TP, Mayrhofer G, et al. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro [J]. Clin Immunol, 2008, 27: 330-339.
28. Steinberg M. Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic [J]. Clin Ther, 2007, 29: 2289-2308.
29. Xia WL, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFRJerbB2 and downstream Erkl/2 and AKT pathways [J]. Oncogene, 2002, 21: 6255-6263.
30. Wood ER, Truesdale AT, Mcdonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells [J]. Cancer Res, 2004, 64: 6652-6659.
31. Spector NL, Xia W, Bums H, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies [J]. J Clin Oncol, 2005, 23: 2502-2512.
32. Weisberg E, Manley P, Mestan J, et al. AMN1O7 (nilotinib): A novel and selective inhibitor of BCR-ABL [J]. Br J Cancer, 2006, 94: 1765-1769.
33. Weisberg E, Manley P, Breitenstein W, et al, Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl [J]. Cancer Cell, 2005,7: 129-141.
34. Dequchi Y, Kimura S. Ashihara E, et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines [J]. Leuk Res, 2008, 32: 980-983.
35. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL [J]. N Engl J Mcd, 2006, 24: 2542-2551.
36. Wheeler C, Stephens T, Byth K, et al. Novel approaches in oncology at AstraZeneca [J]. Eur J Cancer Suppl, 2003, 1: 3-8.
37. Lanzi C, Giuliana C, Valentina N, et al. Targeting RET for thyroid cancer therapy [J]. Biochem Pharmacol, in Press, corrected proof, available online 6 November 2008.
38. Arao T, Fukumoto H, Takeda M, et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474 [J]. Cancer Res, 2004, 64: 9101-9104.
39. Holden SN, Eckhardt SG Basser R, et al. Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors: Results from a phase I study [J]. EurJ Cancer, 2001, 36: S73.
40. Ranson M, Bodkin D, Govindan R, et al. Results of a randomized, double-blind phase II trial of ZD6474 versus gefit inib in patients with NSCLC [J]. Eur J Cancer Suppl, 2005, 3: 324-325.
41. Sonpavde G, Hutson TE. Pazopanib: A novel multitargeted tyrosine kinase inhibitor [J]. Curr Oncol Rep, 2007, 9: 115-119.
42. Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma [J]. Proc Natl Acad Sci USA, 2006, 103: 19478-19483.
43. Kualacz E, Perry B, Sawyer P, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models [J]. Am J Transplant, 2004,4: 51-57.
44. http://www.clinicaltrials.gov/
45. Kualacz E, Conklyn M, Andresen C, et al. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in amurine model of pulmonary eosinophilia [J]. Eur J Pharmacol, 2008, 582: 154-161.
46. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C [J]. J Clin Oncol, 2001, 19: 1485-1492.
47. Miliward Mi, House C, Bowtell D, et al. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: A phase IIA clinical and biologic study [J]. Br J Cancer, 2006, 95: 829-834.
48. Manley PW, Furet P, Bold G, et al. Anthranilic acid amides: A novel class of antiangiogenic VEGF receptor kinase inhibitors [J]. J Med Chem, 2002, 45: 5687-5693.
49. Lv JL, Wang R, Liu D, et al. Design, synthesis, and antitumor activities of some novel substituted 1, 2, 3-benzotriazines [J]. Molecules, 2008, 13: 1427-1440.
50. Giles FJ, List AF, Carroll M, et al. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia [J]. Leuk Res, 2007, 31: 891-897.
51. Drevs J, Müller-Driver R, Wittig C, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosme kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging [J]. Cancer Res, 2002, 62: 4015-4022.
52. Lee L, Sharma S, Morgan B, et al. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTKJZK): Translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases [J]. Cancer Chemother Pharmacol, 2006, 57: 761-771.
53. Trost BM, Tang WP. An enantioselective strategy to macro-cyclic bisindolylmaleimides. An efficient formal synthesis of LY 333531 [J]. Org Lett, 2001,3:3409-3411.
54. Caille JC, Govindan CK, Junga H, et al. Hetero Diels-Alderbiocatalysis approach for the synthesis of (S)-3-[2-{(methylsulfonyl)oxy)ethoxy]-4- (triphenylmethoxy)-l-butanol methanesulfonate, a key intermediate for the synthesis of the PKC inhibitor LY333531 [J]. Org Proc Res Dev, 2002, 6: 471-476.
55. Komander D, Kular GS, Deak M, et al. Interactions of LY33353 1 and other bisindolyl maleimide inhibitors with PDK1 [J]. Structure, 2004, 12: 215-226.
56. Bartlett S, Beddard GS, Jackson RM, et al. Comparison of the ATP binding sites of protein kinases using conformationally diverse bisindolylmaleimides [J]. J Am Chem Soc, 2005, 127: 11699-11708.
57. Alva G Neervannan S. Hydrate forms of AMG7O6: US, 20080039501 [P1, 2007-01-26.
58. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts [J]. Cancer Res, 2006, 66: 8715-8721.
59. Wilmes LJ, Pallavicini MG Fleming LM, et al. AG-0l3736, a novel inhibitor of VEGF receptor tyrosine kjnases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging [J]. Magn Reson Imaging, 2007, 25: 319-327.
60. Rixe O, Bukowscki RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study [Jj. Lancet Oncol, 2007, 8: 975-984.
61. Rinaldi A, Kwee I, Bertoni F, et al. 195 POSTER pharmacogenoniic analysis of the peripheral blood cell transcriptome in patients with advanced solid tumors treated with the mTOR inhibitor deforolimus (AP23573; MK 8669) in phase Ib studies [J]. Eur J Cancer Suppl, 2008, 6: 62.
62. Deforolimus (AP23573) in treatment of sarcoma - SUCCEED (sarcoma multi-center clinical evaluation of the efficacy of deforolimus) study. Clinical Trials gov (2008-03-07).
63. Salgia R, Hong DS, Camacho LH, et al. A phase I dose-escalation study of the safety and pharmacokinetics of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients with advanced malignancies [J]. J Clin Oncol, 2007, 25(18S): 14031.
64. Janne PA, Wax M, Leach J, et al. Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: Impact of preclinical studies on clinical trial design. www.exelixis.com/eortc/posters/EORTCO8-552- XL184-202.pdf
65. Yang J, Chen ZL. Advance in angiogenesis and tumor growth [J]. J Zhejiang Univ (Med Sci) (Japanese Source), 2001, 30: 189-192.
66. Frantz S. Drug discovery: playing dirty [Jj. Nature, 2005, 437: 942-943.
67. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets [J]. Nat Rev Drug Discov, 2006, 5: 821-834.